Omeros (NASDAQ:OMER) Stock Rating Upgraded by StockNews.com

Omeros (NASDAQ:OMER - Get Free Report) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating in a research report issued on Thursday.

OMER has been the subject of a number of other research reports. RODMAN&RENSHAW raised shares of Omeros to a "strong-buy" rating in a research report on Thursday, November 14th. Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday, November 14th. They set a "buy" rating and a $9.00 price target on the stock. Cantor Fitzgerald reiterated a "neutral" rating on shares of Omeros in a research report on Thursday, November 14th. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research report on Friday, January 17th. Finally, D. Boral Capital reissued a "buy" rating and issued a $36.00 price target on shares of Omeros in a research note on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Omeros has an average rating of "Moderate Buy" and a consensus target price of $22.50.

Omeros Stock Performance

NASDAQ OMER opened at $8.01 on Thursday. The firm's 50 day moving average price is $8.90 and its 200-day moving average price is $7.12. Omeros has a 52-week low of $2.61 and a 52-week high of $13.60. The company has a market cap of $464.18 million, a PE ratio of -3.47 and a beta of 2.03.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Barclays PLC boosted its holdings in shares of Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company's stock valued at $376,000 after buying an additional 51,873 shares in the last quarter. State Street Corp raised its position in Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock valued at $4,867,000 after purchasing an additional 3,839 shares during the last quarter. HighTower Advisors LLC raised its position in Omeros by 7.2% in the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company's stock valued at $235,000 after purchasing an additional 4,000 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Omeros in the 3rd quarter valued at $305,000. Finally, MML Investors Services LLC raised its position in Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 3,000 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads